Drug Trial Radar · NCT00337103
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Last checked: Nov 19, 2026Latest source record: Jun 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,276
Actual
Start
Sep 20, 2006
Primary completion
Mar 12, 2012
Study completion Dec 11, 2017
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jun 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.
Conditions
- Metastatic Breast Cancer
Interventions
Eribulin MesylateDrug
1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
CapecitabineDrug
Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years
- Progression Free Survival (PFS)Time frame: From date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years
Locations
169 sites in 23 countries. Site status is shown where the registry gives one.
Site not named
Anaheim, California
Site not named
La Verne, California
Site not named
Poway, California
Site not named
Centralia, Illinois
Site not named
Augusta, Maine
Site not named
Boston, Massachusetts
Site not named
Jefferson City, Missouri
Site not named
Lebanon, New Hampshire
Site not named
Ephrata, Pennsylvania
Site not named
Cookeville, Tennessee
Site not named
Germantown, Tennessee
Site not named
Amarillo, Texas
Site not named
Wenatchee, Washington
Site not named
Bahía Blanca, Argentina
Site not named
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Ciudad Autonoma, Argentina
Site not named
Mendoza, Argentina
Site not named
Santa Fe, Argentina
Hospital General de Agudos Teodoro Alvarez
Ciudad Autonoma, Buenos Aires, Argentina
Instituto Argentino de Diagnostico y Tratamiento
Cuidad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site not named
La Plata, Buenos Aires, Argentina
Site not named
La Plata, Buenos Aires, Argentina
Site not named
Pilar, Buenos Aires, Argentina
Corporacion Medica General San Martin
San Martín, Buenos Aires, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
San Miguel de Tucumán, Tucumán Province, Argentina
Epworth Freemasons Hospital
East Melbourne, Australia
Sir Charles Gairdner Hospital, Dept. of Medical Oncology
Nedlands, Australia
Mater Adult Hospital
South Brisbane, Australia
Bankstown Hospital, Oncology Trials Unit
Bankstown, New South Wales, Australia
Site not named
Hornsby, New South Wales, Australia
Liverpool Hospital, Cancer Therapy Centre
Liverpool, New South Wales, Australia
Ashford Cancer Centre
Adelaide, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Saint Vincent's Hospital
Fitzroy, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
OLVZ Aalst, Oncology Service
Aalst, Belgium
Institut Jules Bordet, Medical Oncology Unit
Brussels, Belgium
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.